Tirzepatide, also known as Mounjaro™, is a GLP-1 drug that is taken once-weekly as an injectable to promote weight loss by regulating blood sugars and reducing hemoglobin A1C levels. Tirzepatide works similarly to the other drugs in the GLP-1 family, but it contains an extra molecule that may give it a slight edge.
The medication has a dual-action design, mimicking the action of two unique incretin hormones involved in blood sugar control: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This unique dual action makes it the first-in-class medication that acts on both of these receptors.
GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, therefore resulting in weight reductions. When combined with the GLP-1 receptor agonist, GIP usage may have a greater impact on markers of metabolic dysregulation, such as body weight, glucose and lipids.
On average, patients lose up to 22.5% of their body weight on this program.